In the same line, Jeong et al. compared the action of the 10-weeks-treatment with two antiplatelet drugs, the P2Y12 receptor antagonists ticagrelor and prasugrel, assessing that only the first one was able to increase the level of EPCs (CD34+KDR+/CD34+CD117+/CD34+CD133+) in T2DM patients with non–ST-segment elevation acute coronary syndrome. The gene discussed is CD34; the disease is type 2 diabetes mellitus.